Donald Seldin Lecture - Tianxin Yang, MD, PhD, FAHA
Tianxin Yang, MD, PhD, FAHA
University of Utah Health
Salt Lake, UT
Tianxin Yang is a professor of medicine and physiology, Dialysis Research Foundation Endowed Chair at the University of Utah and senior research career scientist at VA Salt Lake City Health Care System.
Dr. Yang is a distinguished scientist who has made seminal contributions to understanding physiological processes for renal control of salt and water and blood pressure.
Particularly important are his recent discoveries on the roles of soluble (pro)renin receptor (sPRR) and intrarenal renin-angiotensin system in renal physiology and pathophysiology. His research in this area is groundbreaking and translational.
Dr. Yang’s accomplishments are highlighted by numerous prestigious honors and awards, including the Harry Goldblatt New Investigator from the American Heart Association Council on Hypertension; AHA Established Investigator Award; Senior Research Career Scientist Award from the Department of Veterans Affairs; Lewis K. Dahl Lecture from the Council on Hypertension; and this year’s Donald Seldin Lecture from the AHA Council on the Kidney in Cardiovascular Disease.
He has published 189 peer-reviewed articles and served on editorial boards of the Journal of American Society of Nephrology, Hypertension and American Journal of Physiology-Renal Physiology.
He has delivered over 100 invited lectures at scientific meetings and academic institutions. He holds multiple patents on novel technologies for the treatment of kidney disease and hypertension, some of which have reached the clinical stage of drug development.
In 2023, he co-founded NephroNovus, LLC to develop inhibitors of the intrarenal RAS.
Dr. Yang is a distinguished scientist who has made seminal contributions to understanding physiological processes for renal control of salt and water and blood pressure.
Particularly important are his recent discoveries on the roles of soluble (pro)renin receptor (sPRR) and intrarenal renin-angiotensin system in renal physiology and pathophysiology. His research in this area is groundbreaking and translational.
Dr. Yang’s accomplishments are highlighted by numerous prestigious honors and awards, including the Harry Goldblatt New Investigator from the American Heart Association Council on Hypertension; AHA Established Investigator Award; Senior Research Career Scientist Award from the Department of Veterans Affairs; Lewis K. Dahl Lecture from the Council on Hypertension; and this year’s Donald Seldin Lecture from the AHA Council on the Kidney in Cardiovascular Disease.
He has published 189 peer-reviewed articles and served on editorial boards of the Journal of American Society of Nephrology, Hypertension and American Journal of Physiology-Renal Physiology.
He has delivered over 100 invited lectures at scientific meetings and academic institutions. He holds multiple patents on novel technologies for the treatment of kidney disease and hypertension, some of which have reached the clinical stage of drug development.
In 2023, he co-founded NephroNovus, LLC to develop inhibitors of the intrarenal RAS.